Pharmaceuticals - Sudan

Sudan

The Pharmaceuticals market in Sudan is expected to witness a significant growth in revenue, with projections indicating that it will reach US$258.40m in 2024.
among the various markets of the market, Oncology Drugs stands as the largest market, with a projected market volume of US$10.59m in 2024.
This signifies the growing importance of oncology drugs in the country's pharmaceutical landscape.
Furthermore, the revenue in the Pharmaceuticals market is anticipated to display a steady annual growth rate of -2.27%, as per the compound annual growth rate (CAGR) estimated for the period 2024-2029.
This growth trajectory is expected to result in a market volume of US$230.40m by 2029.
These statistics highlight the positive outlook and potential for expansion within Sudan's pharmaceutical market.
When comparing in Sudan to the global pharmaceutical market, it is worth noting that United States is projected to generate the highest revenue, amounting to US$630.30bn in 2024.
This stark contrast emphasizes the dominance of the US market on a global scale, while also highlighting the potential for further growth and development within Sudan's pharmaceutical sector.
Sudan's pharmaceutical market is experiencing a surge in demand for essential medicines due to increasing healthcare awareness and a growing population.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Next generation therapies are also part of the Pharmaceuticals market and include gene therapy, cell therapy, and nucleic acid therapy. Cell therapies involve the use of living cells to replace or repair damaged tissues within the patient's body, or to modify cells to perform specific functions. Gene therapies focus on altering a patient’s genetic material to regulate the production of certain proteins. Nucleic acid therapies use short strands of DNA or RNA to inhibit the production of harmful proteins associated with diseases and promote the generation of therapeutic proteins. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Sudan has been steadily growing in recent years, driven by several factors that are unique to the country.

Customer preferences: Sudan has a large population that is increasingly becoming health-conscious and seeking better access to healthcare services. This has led to a growing demand for pharmaceutical products, particularly those that treat chronic diseases such as diabetes and hypertension.

Trends in the market: One of the key trends in the pharmaceuticals market in Sudan is the increasing adoption of generic drugs. This is due to the fact that generic drugs are more affordable than their branded counterparts, making them more accessible to a larger segment of the population. Additionally, the government has implemented policies to encourage the use of generic drugs, which has further boosted their popularity in the country. Another trend that is shaping the pharmaceuticals market in Sudan is the increasing use of technology in healthcare. This includes the use of telemedicine and mobile health apps, which are helping to improve access to healthcare services in remote areas of the country. This trend is likely to continue as the government invests in improving healthcare infrastructure and promoting the use of technology in healthcare.

Local special circumstances: Sudan has a challenging business environment, with a high level of political and economic instability. This has made it difficult for pharmaceutical companies to operate in the country, particularly those that rely on imports of raw materials and finished products. Additionally, the country has a weak regulatory environment, which has led to concerns about the quality and safety of pharmaceutical products on the market.

Underlying macroeconomic factors: The Sudanese economy has been struggling in recent years, due to a combination of factors including political instability, economic sanctions, and the impact of COVID-19. This has led to a depreciation of the Sudanese pound, which has made it more expensive for pharmaceutical companies to import raw materials and finished products. Additionally, the country has a large informal economy, which has made it difficult for the government to collect taxes and regulate the pharmaceutical market effectively. In conclusion, while the pharmaceuticals market in Sudan is growing, it is facing several challenges that are unique to the country. These include a weak regulatory environment, a challenging business environment, and an unstable macroeconomic situation. However, the increasing adoption of generic drugs and the use of technology in healthcare are positive trends that are likely to continue to shape the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.